Findings

What do systematic reviews say?

178 questions · 179 findings · 80 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 104 · 58.1%GRADE not reported 6 · 3.4%Very low 18 · 10.1%Low 31 · 17.3%Moderate 16 · 8.9%High 4 · 2.2%

Topical quinolone vs povidone‐iodine

Quality of life ‐ not measured · chronic suppurative otitis media

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics versus topical antiseptics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alitretinoin vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Health‐related quality of life · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tissue plasminogen activator (t‐PA) vs usual care

Quality of life measures at 1 month · people with acute non‐arteritic CRAO

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for acute non‐arteritic central retinal artery occlusion 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily)

Improvements in quality of life measures · patients with established cardiomyopathy in DMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group A: amino acids vs placebo

Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Mean quality of life ‐ health utility · adults with acute spontaneous intracerebral haemorrhage

1 finding from 1 review

Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2349 participants
High

Minoxidil vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

α‐tocopheryl quinone vs placebo

Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

α‐tocopheryl quinone vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Moderate

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benralizumab 10 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 680 participants
Moderate

Benralizumab 30 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1333 participants
Moderate

Benralizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1351 participants
High

Mepolizumab 300 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 451 participants
Moderate

Mepolizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 911 participants
Moderate

Macrolides vs tetracycline

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found